All In Biotech

Drug Trial Radar · NCT03005288

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Feb 1, 2017

Primary completion

Mar 21, 2019

Study completion May 8, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • BYM338 10 mg/kgDrug

    intravenous infusion every four weeks

  • PlaceboOther

    intravenous infusion every four weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Body Fat Mass by Dual Energy X-ray Absorptiometry (DXA) at Week 48Time frame: Baseline, Week 48

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Anaheim, California

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami Lakes, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Berlin, New Jersey

  • Novartis Investigative Site

    Eatontown, New Jersey

  • Novartis Investigative Site

    Merthyr Tydfil, Mid Glamorgan, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.